Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | BCHE | P06276 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 5/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3427787 | 0.90 | TDP1 (0.61) | L3MBTL1TDP1BCHEMAOBMAOA | |
| SCHEMBL3423447 | 0.85 | L3MBTL1 (0.76) | L3MBTL1TDP1SMN1; SMN2BCHEMAPK1 | |
| SCHEMBL3425323 | 0.81 | LMNA (0.60) | L3MBTL1TDP1SMN1; SMN2MAPK1RAB9A | |
| SCHEMBL8829504 | 0.78 | L3MBTL1 (0.67) | L3MBTL1TDP1SMN1; SMN2MAPK1 | |
| Hydrochloric Acid SCHEMBL15238737 | 0.77 | L3MBTL1 (0.70) | L3MBTL1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL3428392 | 0.76 | L3MBTL1 (0.61) | L3MBTL1TDP1BCHEMAOB | |
| SCHEMBL3425259 | 0.74 | BCHE (0.52) | L3MBTL1TDP1SMN1; SMN2BCHEMAOB | |
| SCHEMBL964244 | 0.74 | SPHK2 (0.67) | MAOBMAOANR4A2 | |
| SCHEMBL3423751 | 0.74 | TDP1 (0.74) | L3MBTL1TDP1BCHEMAPK1 | |
| SCHEMBL16710557 | 0.71 | MAOB (0.77) | MAOBMAOANR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7649005-B2 | (R)(4-Pentyloxy-benzyl)-(tetrahydro-furan-2-ylmethyl)-amine; monoamine oxidase inhibitors; neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urologic, metabolic and gastrointestinal diseases | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-01-19 | — | — | US | claimed |
| US-20070135496-A1 | Substituted benzylaminoalkylene heterocycles | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-06-14 | — | — | US | claimed |
| EP-1673356-A1 | SUBSTITUTED BENZYLAMINOALKYLENE HETEROCYCLES | Newron Pharmaceuticals S.p.A. (IT) | 2006-06-28 | — | — | EP | claimed |
| WO-2005040138-A1 | SUBSTITUTED BENZYLAMINOALKYLENE HETEROCYCLES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-05-06 | — | — | WO | claimed |
| EP-1524267-A1 | Substituted benzylaminoalkylene heterocycles | Newron Pharmaceuticals S.p.A. (IT) | 2005-04-20 | — | — | EP | claimed |
| US-7649005-B2 | (R)(4-Pentyloxy-benzyl)-(tetrahydro-furan-2-ylmethyl)-amine; monoamine oxidase inhibitors; neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urologic, metabolic and gastrointestinal diseases | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-01-19 | — | — | US | disclosed |
| US-20070135496-A1 | Substituted benzylaminoalkylene heterocycles | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-06-14 | — | — | US | disclosed |
| EP-1673356-A1 | SUBSTITUTED BENZYLAMINOALKYLENE HETEROCYCLES | Newron Pharmaceuticals S.p.A. (IT) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005040138-A1 | SUBSTITUTED BENZYLAMINOALKYLENE HETEROCYCLES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-05-06 | — | — | WO | disclosed |
| EP-1524267-A1 | Substituted benzylaminoalkylene heterocycles | Newron Pharmaceuticals S.p.A. (IT) | 2005-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135496-A1 | Substituted benzylaminoalkylene heterocycles | HTR7, MAOB, CYP2A7 | L3MBTL1 3150/4885TDP1 3447/4885SMN1; SMN2 2117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.